Page 87 - 77_04

SÍNTESIS
DE
INHIBIDORES
SELECTIVOS
MMP-­-2….

26.
Kolodziej.,
S.A,
&
al.
(2010).
Orally
bioavailable
dual
MMP-­-1/MMP-­-14
sparing,
MMP-­-13

selective
alpha-­-sulfone
hydroxamates.
Bioorganic
&
Medicinal
Chemistry
Letters,
20(12),

3557-­-3560.

27.
Kolodziej,
S.A.,
&
al.
(2010).
MMP-­-13
selective
isonipecotamide
alpha-­-sulfone
hydroxamates.

Bioorganic
&
Medicinal
Chemistry
Letters,
20(12),
3561-­-3564.

28.
Skiles,
J.W.,
&
al.
(2004).
The
design,
structure,
and
clinical
update
of
small
molecular
weight

matrix
metalloproteinase
inhibitors.
Current
Medicinal
Chemistry,
11(22),
2911-­-2977.

29.
Manetsch,
R.,
&
al.
In
situ
click
chemistry:
Enzyme
inhibitors
made
to
their
own
specifications.

Journal
of
the
American
Chemical
Society,
(2004).
126(40),
12809-­-12818.

30.
Lewis,
W.G,
et
al.
(2002).
Click
chemistry
in
situ:
Acetylcholinesterase
as
a
reaction
vessel
for

the
selective
assembly
of
a
femtomolar
inhibitor
from
an
array
of
building
blocks.
Angewandte

Chemie-­-International
Edition,
41(6),
1053-­-1057.

31.
Krasinski,
A.,
&
al.
(2005).
In
situ
selection
of
lead
compounds
by
click
chemistry:
Target-­-

guided
optimization
of
acetylcholinesterase
inhibitors.
Journal
of
the
American
Chemical

Society,
127(18),
6686-­-6692.

32.
Whiting,
M.,
&
al.
(2006).
Inhibitors
of
HIV-­-1
protease
by
using
in
situ
click
chemistry.

Angewandte
Chemie-­-International
Edition,
45(9),
1435-­-1439.

33.
Giffin,
M.J.,
&
al.
(2008).
A
Copper(I)-­-Catalyzed
1,2,3-­-Triazole
Azide-­-Alkyne
Click
Compound
is

a
Potent
Inhibitor
of
a
Multidrug-­-Resistant
HIV-­-1
Protease
Variant.
Journal
of
Medicinal

Chemistry,
51(20),
6263-­-6270.

34.
Kalesh,
K.A.,
&
al.
(2009).
Rapid
synthesis
of
Abelson
tyrosine
kinase
inhibitors
using
click

chemistry.
Organic
&
Biomolecular
Chemistry,
7(24),
5129-­-36.

35.
Carvalho,
I.,
&
al.
(2010).
'Click
chemistry'
synthesis
of
a
library
of
1,2,3-­-triazole-­-
substituted

galactose
derivatives
and
their
evaluation
against
Trypanosoma
cruzi
and
its
cell
surface
trans-­-
sialidase.
Bioorganic
&
Medicinal
Chemistry,
18(7),
2412-­-2427.

36.
Ng,
S.L.,
&
al.
(2008).
Click
synthesis
of
small-­-molecule
inhibitors
targeting
caspases.
Organic
&

Biomolecular
Chemistry.

37.
Wang.,
J,
&
al.
(2006).
Rapid
assembly
of
matrix
metalloprotease
inhibitors
using
click

chemistry.
Organic
Letters,
8(17),
3821-­-3824.

38.
GLIDE
(2003).
Glide
v
2.5021.
Schrödinger,
L.L.C.,
New
York,
USA.

39.
Feng,
Y.Q.,
&
al.
(2002).
Solution
structure
and
backbone
dynamics
of
the
catalytic
domain
of

matrix
metalloproteinase-­-2
complexed
with
a
hydroxamic
acid
inhibitor.
Biochimica
Et

Biophysica
Acta-­-Proteins
and
Proteomics,
1598(1-­-2),
10-­-23.

40.
Garcia,
M.A.,
&
al.
(2007).
Are
adrenomedullin
positive
modulators
novel
matrix

metalloproteinase
inhibitors?
Anales
de
la
Real
Academia
de
Farmacia;
Instituto
de
España,
73,

703-­-724.

41.
Garcia,
M.A.
(2007).
Estudio
de
interacciones
ligando-­-receptor
mediante
técnicas

computacionales.
La
adrenomedulina
y
las
metaloproteasas
de
la
matriz
como
dianas
para
el

diseño
racional
de
fármacos.
Tesis
Doctoral
Universidad
San
Pablo
CEU.

42.
Friesner,
R.A.,
&
al.
(2006).
Extra
precision
glide:
docking
and
scoring
incorporating
a
model
of

hydrophobic
enclosure
for
protein-­-ligand
complexes.
J
Med
Chem,
49(21),
6177-­-96.

43.
MacPherson,
L.J.,
&
al.
(1997).
Discovery
of
CGS
27023A,
a
non-­-peptidic,
potent,
and
orally

active
stromelysin
inhibitor
that
blocks
cartilage
degradation
in
rabbits.
J
Med
Chem,
40(16),

2525-­-2532.

44.
Serra.

(2009).
Estrategias
computacionales
para
el
estudio
de
la
inhibición
de
metaloproteasa

de
la
matriz-­-2.
Diseño
de
inhibidores.
DEA
Universidad
San
Pablo
CEU.

45.
Overall,
C.M.,
&
Lopez-­-Otin,
C.
(2002).
Strategies
for
MMP
inhibition
in
cancer:
Innovations
for

the
post-­-trial
era.
Nature
Reviews
Cancer,
2(9),
657-­-672.

117